
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera Inc is poised for significant revenue growth, particularly driven by its Signatera test in oncology, as evidenced by a robust quarter with a 54% year-over-year increase in MRD volumes. The company’s expansion of reimbursement coverage across additional cancer types is expected to enhance average selling prices and contribute positively to gross margins and operating cash flow. Furthermore, Natera's notable revenue beat of approximately $80 million in Q3 and a raised guidance for 2025 by $160 million signal strong financial momentum and an optimistic outlook for the company.
Bears say
Natera Inc faces significant challenges that could negatively impact its financial outlook, primarily due to expected margin erosion from reductions in in-network pricing as its total addressable market (TAM) expands to include average-risk patients. Additionally, any adverse events such as regulatory setbacks, reimbursement issues, or disappointing financial results could further depress the stock's performance. The company's dependency on compelling data and successful expansion plans, coupled with the inherent risks in emerging markets, raises concerns about its overall growth potential and market position.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares